Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
A new US drug spending report from IQVIA parses out how rebates impact drug spending and explores affordability for patients. The data show drug makers offset about 28% of drug spending and provide some support to industry's arguments on drug pricing.
Latest From Pricing Debate
Hans Bijlsma, president of the European League Against Rheumatism, tells Scrip about the progress being made in rheumatic and muskuloskeletal diseases, the areas where more innovation is needed and the importance of early treatment, both clinically and financially.
PRIMA, the new service the National Institute for Health and Care Excellence offers to review economic models, must not be affected by confidentiality and conflict of interest issues, warns UK the pharmaceutical industry group, ABPI.
Third US Senate committee hearing on 340B reforms focuses on the need for legislation requiring that providers report the drug discounts received and how they use the savings, but prospects for achieving change are unclear.
The Creating and Restoring Equal Access to Equivalent Samples Act clears US Senate Judiciary Committee. During markup, Sens. Hatch, R-Utah, and Cornyn, R-Tex., preview future amendments that would benefit innovators.
Senate Health, Education, Labor and Pensions Committee Chair Lamar Alexander noted panel's lack of consensus on drug pricing policies advanced by the Trump Administration during June 12 hearing.
Democrats on US Senate Health Committee express concern that patient cost sharing could increase significantly with the change.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.